Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359242 | 1.00 | MAPT (0.56) | MAPTRAB9ANPC1SLC6A2SLC6A4 | |
| SCHEMBL1100342 | 0.85 | LMNA (0.44) | MAPTRAB9ANPC1SLC6A2SLC6A4 | |
| SCHEMBL7001425 | 0.84 | RAB9A (0.57) | MAPTRAB9ANPC1NAAAKDM1A | |
| SCHEMBL432751 | 0.84 | RAB9A (0.57) | MAPTRAB9ANPC1NAAAKDM1A | |
| SCHEMBL14097153 | 0.84 | ALDH1A1 (0.63) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL16229142 | 0.84 | DEGS1 (0.50) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL18596476 | 0.84 | RAB9A (0.57) | MAPTRAB9ANPC1NAAAKDM1A | |
| SCHEMBL1100407 | 0.84 | DEGS1 (0.50) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL10289077 | 0.84 | RAB9A (0.57) | MAPTRAB9ANPC1NAAAKDM1A | |
| SCHEMBL15430481 | 0.84 | DEGS1 (0.50) | SLC6A2SLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2021-05-20 | — | — | US | disclosed |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200095214-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3030323-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3030323-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-09-08 | — | — | US | disclosed |
| EP-3030323-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| CN-105592888-A | Kdm1a inhibitors for the treatment of disease | IMAGO BIOSCIENCES INC | 2016-05-18 | — | — | CN | disclosed |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2015-09-17 | — | — | US | disclosed |
| WO-2015021128-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2015021128-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC. (US) | 2015-02-12 | — | — | WO | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY | 2014-11-20 | — | — | US | disclosed |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | DUKE UNIVERSITY (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2011094890-A1 | PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS | ARGUSINA INC. (US) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343118-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | BRCA1, NAT1, AADAC | MAPT 4340/4885RAB9A 3555/4885NPC1 125/4885 |
| US-20150258044-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | MAPT 304/4885RAB9A 1287/4885NPC1 137/4885 |
| US-10882835-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MAPT 4151/4885RAB9A 3635/4885NPC1 4418/4885 |
| US-20160257662-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MAPT 4157/4885RAB9A 3786/4885NPC1 4405/4885 |
| US-20130178520-A1 | METHODS OF TREATMENT USING ARYLCYCLOPROPYLAMINE COMPOUNDS | SNCA, PARK7, PNMT | MAPT 304/4885RAB9A 1287/4885NPC1 137/4885 |
| US-10370346-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MAPT 4151/4885RAB9A 3635/4885NPC1 4418/4885 |
| US-20200095214-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MAPT 4151/4885RAB9A 3635/4885NPC1 4418/4885 |
| US-20210147373-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MAPT 4151/4885RAB9A 3635/4885NPC1 4418/4885 |
| US-11655226-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MAPT 4151/4885RAB9A 3635/4885NPC1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.